{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-112359","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.555323+00:00","generated_at":"2026-06-09T05:56:31.253762+00:00","sec_items":["1.01","1.02","2.02","3.02","5.08","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"VYNE announces $88M PIPE funding and positive clinical data for VYN201 and VYN202","bullets":["Raised $88M gross from PIPE led by Access Biotechnology, with participation from healthcare investors.","Phase 1b VYN201 vitiligo trial: 1.0% cohort 30.3% mean F-VASI reduction (p=0.0137), 2.0% cohort 39.0% (p=0.0077) vs 0.5%.","VYN202 preclinical: 95% PASI reduction in psoriasis model; 71% reduction in rheumatoid arthritis signs/symptoms.","Preliminary cash $15.5M as of Sep 30, 2023; with PIPE proceeds pro forma $103.7M.","Next steps: Phase 2b VYN201 in vitiligo in 1H2024; Phase 1a VYN202 trial expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-112359","json":"https://secwatch.observer/filing/0001104659-23-112359.json","markdown":"https://secwatch.observer/filing/0001104659-23-112359.md","text":"https://secwatch.observer/filing/0001104659-23-112359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/0001104659-23-112359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/tm2329331d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:56:31.253762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0848edcf48df05d8de18485b085559f784ff39f","claim":"VYNE Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at $88.2 million (effective 2023-10-27).","evidence_excerpt":"On October 27, 2023, VYNE Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/0001104659-23-112359-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and other accredited investors"},{"label":"Value","value":"$88.2 million"},{"label":"Effective","value":"2023-10-27"}],"fact_type":"material_agreement"},{"claim_id":"ff0c1092207c10fd1c028dfc90ca7d34236544c3","claim":"VYNE Therapeutics Inc. terminated Purchase Agreement with Lincoln Park Capital Fund, LLC (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, the Company delivered a notice of termination to Lincoln Park terminating the Purchase Agreement effective as of one business day following delivery of notice.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/0001104659-23-112359-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lincoln Park Capital Fund, LLC"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}